Combination products put pharma and medtech teams on the same filing. That sounds straightforward until the first CMC question arrives and neither team knows who answers it. The reason combo filings slip is almost never the regulation itself; it is the organisational choices made before anyone reads 21 CFR Part 4 or MDR Article 117. This post covers the three decisions that determine everything else, the practical read on what FDA and EMA require, and what integrated teams do differently to ship combo filings without the last-minute scramble.
The three decisions that determine the rest
Combo filings have a regulatory dimension and an organisational dimension. Get the organisational dimension right and the regulatory work gets noticeably faster. Three decisions matter most.
Classification: drug-led or device-led. FDA assigns a primary mode of action (PMOA) through its Office of Combination Products (OCP). EU MDR treats drug-device combos as either integral to the medicine or as a device placed on the market separately. The classification determines the lead regulator and therefore the authoring discipline. Get this wrong in the first six months and the entire file has to be re-scoped.
Lead regulator: FDA OCP assignment and EU Notified Body pre-engagement. On the FDA side, the Office of Combination Products assigns the product to CDER, CBER, or CDRH. Request of Designation (RFD) is the formal route when classification is contested. On the EU side, devices integral to medicinal products go through a Notified Body Opinion (NBOp) under MDR Article 117 before the medicine can be approved. Sponsors that engage the Notified Body late pay a 6-12 month timeline hit.
Internal ownership: who authors what. The lead team (pharma or medtech RA) owns the submission, but specific sections belong to the other team. CMC for the medicinal portion, Design History File or equivalent for the device portion, clinical protocol sections that support both. Without a written ownership matrix, sections land in no-man's-land and get written twice or not at all.
Combine the three decisions in the first month of scoping and the filing de-risks dramatically. Delay them and the work piles up near the submission deadline.
What the rules actually say
The working RA lead needs the compact operational read, not a re-write of the regulation. Here it is.
FDA: 21 CFR Part 4 plus OCP assignment
The primary mode of action determines which centre leads. A drug-led combination product where the drug is the principal mode of action is reviewed by CDER or CBER with CDRH providing device input. A device-led product is reviewed by CDRH with CDER or CBER providing drug input. 21 CFR Part 4 codifies the CGMP requirements for combination products, including the "streamlined approach" that allows a single compliance programme covering both drug and device requirements.
Classification disputes go through a formal Request for Designation (RFD). The FDA OCP page has the current process and timing. Most RFDs resolve in 60 days.
EU: MDR Article 117 for integral devices
MDR Article 117 added a new requirement. A device that is integral to a medicinal product (pre-filled syringe, drug-eluting stent, inhaler) needs a Notified Body Opinion (NBOp) that the device portion meets the MDR Annex I General Safety and Performance Requirements. The NBOp is submitted as part of the EMA or national medicine application. No NBOp, no approval.
Exceptions: devices already CE-marked for their intended purpose, and Class I non-sterile integral devices that do not require a NBOp. Anything else requires Notified Body engagement from early in the development timeline.
Safety reporting and post-market
FDA post-market safety follows the primary reporting channel of the lead centre. A drug-led combo reports adverse events to FAERS (moving to AEMS) under the E2B(R3) standard from October 1, 2026. A device-led combo reports through MedWatch under 21 CFR 803. EU post-market reports flow through EudraVigilance for the medicine portion and the EUDAMED vigilance module for the device portion. Integrated teams configure their safety systems to route a single case file correctly to both channels without duplication.
What integrated teams do differently
Five patterns separate efficient combo teams from the ones that lose six months at the end.
1. Classification kick-off in month one. The pharma RA lead, the medtech RA lead, the clinical lead, and the CMC lead meet in month one with the product development brief and agree the primary mode of action, the likely FDA centre assignment, and the MDR Article 117 applicability. Document the decision. Revisit only if a material design change would alter it.
2. Pre-engagement with FDA OCP and Notified Body in parallel. The FDA pre-IND or pre-submission meeting covers combo classification explicitly. The Notified Body pre-assessment (if applicable) starts at the same time, not after FDA feedback lands. Running these in parallel cuts the combined engagement timeline roughly in half.
3. A written authoring ownership matrix. A one-page document listing every section of the eventual submission (Module 1, 2, 3, 4, 5 for the medicine; DHF or MDR Annex II equivalent for the device; clinical sections; safety sections) with the name of the team or person who owns authoring. Updated whenever the project structure changes. This document is the artefact that prevents "I thought you were writing that section."
4. Integrated CMC and design controls from the start. 21 CFR Part 4 permits a streamlined compliance programme. Teams that build this streamlined programme from day one avoid having to retrofit two parallel compliance systems into one before approval. On the EU side, the same principle applies to MDR Annex II technical documentation and the medicinal CTD.
5. Safety reporting configured for dual routing before first clinical dose. Configuring the safety database to emit both ICH E2B(R3) for FAERS/AEMS and EUDAMED-compatible vigilance reports before first dose is the cheapest time to do it. Retrofitting post-launch is significantly more expensive.
Try this in RegAid: What are the FDA OCP PMOA classification criteria for combination products?
Common pitfalls
Treating the FDA OCP assignment as final. PMOA can be contested late if design changes shift the balance. Integrated teams build a classification-sensitivity analysis into their design freeze to avoid late re-scoping.
Starting Notified Body engagement after pharma regulatory strategy is locked. This guarantees a 6-12 month delay. Bring the Notified Body conversation into the same room as the pharma regulatory strategy discussion from month one.
Assuming that US and EU classifications match. They do not always. A combination product that is drug-led at FDA can require a separate Notified Body engagement at EU level if the device component is integral under MDR. Map both classifications per product.
Splitting the clinical protocol along pharma vs medtech lines. Clinical protocols for combination products should be single documents addressing both the drug and device endpoints. Splitting creates downstream inconsistencies in the CTD and the DHF.
Leaving the authoring ownership matrix undocumented. The most common failure mode. If ownership is verbal, sections fall between desks. Writing the matrix takes an hour. Not writing it costs weeks.
Key takeaways
- Combination product filings are harder organisationally than technically; the three scoping decisions (classification, lead regulator, ownership) in month one determine the rest
- FDA classification follows primary mode of action under 21 CFR Part 4 with OCP assignment to CDER, CBER, or CDRH
- EU devices integral to medicinal products need a Notified Body Opinion under MDR Article 117 as part of the medicine application
- Integrated teams run FDA pre-engagement and Notified Body pre-assessment in parallel, maintain a written authoring matrix, build integrated CMC and design controls from the start, and configure dual safety reporting before first clinical dose
- US and EU classifications are not always equivalent; map both per product
How RegAid helps
Combo filings involve dense cross-reference work between pharma and medtech regulations. RegAid covers 21 CFR Part 4, MDR Article 117, FDA OCP process documents, EMA-NB opinion guidance, ICH E6(R3) and E2B(R3), and the underlying MDR and FD&C Act texts in one cited search layer. When your pharma RA lead needs to answer "what does MDR Article 117 require for a drug-eluting stent?" or your medtech RA lead needs "what FDA CMC data does a drug-led combination require?", ask RegAid, get a cited answer that both teams can verify in the primary source, and keep the classification and ownership matrix current without cross-team search duplication.